Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey ...

We are grateful to the FDA for recognizing the potential of tividenofusp alfa as a meaningful treatment option for individuals with Hunter syndrome. We look forward to continued collaboration with ...

Hunter syndrome affects over 2,000 individuals, primarily males, in commercially accessible regions. With analysts maintaining a Strong Buy consensus and the company maintaining a healthy ...

Hunter x Hunter is one of the most well-known anime series of all time. In fact, viewers consider it the best shonen anime of all time. The studio working on it left no stone unturned and made ...

Aaron Taylor-Johnson in "Kraven the Hunter." Kraven the Hunter—the Marvel movie bust starring Aaron Taylor-Johnson and Russell Crowe—is coming soon to digital streaming. Kraven the Hunter ...

RegenxBio said Tuesday that Kyoto, Japan’s Nippon Shinyaku Co. Ltd. will develop and commercialize its one-time gene therapies for Hunter syndrome and Hurler syndrome, both affecting children.

"Kraven the Hunter" partial poster featuring Aaron Taylor-Johnson. Kraven the Hunter—the Marvel box office bust starring Aaron Taylor-Johnson and Russell Crowe—debuts on digital streaming this ...